Background: We aimed to investigate the characteristics and pretreatment risk factors for postoperative pulmonary complications (PPCs) after neoadjuvant concurrent chemoradiotherapy (CRTx) in patients with non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed data of 122 patients who underwent curative resection after neoadjuvant CRTx for NSCLC between 2007 and December 2019. Clinical data, including pulmonary function and body mass index (BMI) at the time of concurrent CRTx initiation, were analyzed. We performed logistic regression analyses to identify the risk factors for PPCs and built a nomogram with significant factors. Results: Of the 122 patients included (mean age, 60.1 ± 9.7 years; 69.7% male), 27 experienced ...
OBJECTIVES: The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively ...
Purpose/Objective(s) A subset analyses of randomized intergroup trial (INT0139) published in 2009, ...
Background: The utilization of neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy has i...
Aim: The aim of this study was to investigate the factors that affect mortality and morbidity (MM) i...
Abstract The aim of this study was to identify predictors of postoperative outcome and survival of l...
Video-assisted thoracoscopic surgery (VATS) is regarded as the standard treatment for lung cancer. H...
ObjectiveWe previously reported a high mortality after induction therapy and pneumonectomy for non-s...
PURPOSE: To evaluate the prognostic factors associated with survival in patients treated with neoad...
Most studies analyzing risk factors for pulmonary morbidity date from the early 1990s. Changes in te...
BACKGROUND Postoperative pulmonary complications (PPCs) are associated with poor outcomes followi...
BACKGROUND Although some studies seem to indicate a positive prognostic value of induction chemother...
IntroductionA main drawback of neoadjuvant chemotherapy is that it may increase operative morbidity ...
IntroductionOptimal management of clinical stage IIIA-N2 non–small-cell lung cancer (NSCLC) is contr...
Abstract Background The risk factors for postoperative complications after pulmonary resection in pa...
The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic f...
OBJECTIVES: The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively ...
Purpose/Objective(s) A subset analyses of randomized intergroup trial (INT0139) published in 2009, ...
Background: The utilization of neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy has i...
Aim: The aim of this study was to investigate the factors that affect mortality and morbidity (MM) i...
Abstract The aim of this study was to identify predictors of postoperative outcome and survival of l...
Video-assisted thoracoscopic surgery (VATS) is regarded as the standard treatment for lung cancer. H...
ObjectiveWe previously reported a high mortality after induction therapy and pneumonectomy for non-s...
PURPOSE: To evaluate the prognostic factors associated with survival in patients treated with neoad...
Most studies analyzing risk factors for pulmonary morbidity date from the early 1990s. Changes in te...
BACKGROUND Postoperative pulmonary complications (PPCs) are associated with poor outcomes followi...
BACKGROUND Although some studies seem to indicate a positive prognostic value of induction chemother...
IntroductionA main drawback of neoadjuvant chemotherapy is that it may increase operative morbidity ...
IntroductionOptimal management of clinical stage IIIA-N2 non–small-cell lung cancer (NSCLC) is contr...
Abstract Background The risk factors for postoperative complications after pulmonary resection in pa...
The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic f...
OBJECTIVES: The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively ...
Purpose/Objective(s) A subset analyses of randomized intergroup trial (INT0139) published in 2009, ...
Background: The utilization of neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy has i...